Session	Start-ups/SMEs looking for Finance: Series A and Series B/C Funding
Title	XGOS - Reduces feed cost and increases health in poultry. Only scale up needed for market introduction
Company	aspratis GmbH
Speaker	Laeufer Albrecht
TRL	TRL 4-7
Keywords feedstock (max 2)	xyloglucane crops
Keywords technology (max 2)	enzymatic hydrolysis
Keywords End-Product (max 2)	defined xylooligosaccarides

Abstract:

aspratis has developed a novel, very defined xyloglucano-oligo-saccharide (XGOS) with mostly 7-, 8-, and 9-mers for use in feed, food and health. Proof of concept has been achieved in 7 broiler feeding trials and one ex vivo study. aspratis-XGOS is acting as a "stimbiotic". It stimulates at very low dosages the microbiome to increase feed conversion efficiency, body weight gain and overall livability. In one trial under coccidiosis challenge aspratis-XGOS performed equally well to Narasine, an established antibiotic. The holoanalysis of the trial data showed good statistical relevance.

The missing element until market introduction is scale up to commercial production. Custom manufacturing facilities including pilot have been secured. The process itself is straightforward. Investment need is 1.5m€, time to break even 1-1.5 years, >50m€ accumulated revenue within 5 years. The broiler producer will obtain 6-8€ of value for each € spent.

Behind aspratis-XGOS stands a seasoned management team with extremely deep experience in the global animal nutrition industry.